Bio-Techne

Company Overview

Bio-Techne deals in life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets globally. Its products include the complementary brands R&D Systems, Novus Biologicals, Tocris, Protein Simple, and Bios Pacific. The company has brought these brands together as Bio-Techne to be a more substantial scientific partner to help customers attain their research goals. During fiscal year 2023, Bio-Techne operated under two operating segments: Protein Sciences, Diagnostics, and Genomics. The Protein Sciences segment offers high-quality biological reagents and proteomic analytical tools. The Diagnostics and Genomics segment deals in diagnostic products, such as advanced tissue-based in-situ hybridization assays for tissue biopsy and spatial genomic analysis, exosome-based molecular diagnostic assays, controls, calibrators, and diagnostic assays for the regulated diagnostics market.

The company’s products include complementary brands such as R&D Systems, Novus Biologicals, Tocris, Protein Simple, Advanced Cell Diagnostics Inc. (ACD), and Exosome Diagnostics. R&D Systems is the first company in biotechnology to commercially market the multifunctional cytokine TGF-beta 1. It is a producer of immunoassays, arrays, antibodies, cell selection and detection products, and stem cell products, among other cell biology tools.

Bio-Techne operates globally, with offices throughout North America, Europe, and Asia. Today, product lines extend to over 350,000 products, most of which are manufactured in multiple locations in North America, the U.K., and China.

Financial Highlights (FY 2024)

Company's Business Segments

• Protein Sciences : Proteomic analytical tools, both manual and automated, developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy.
• Diagnostics and Genomics : Develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.